BioNTech SE ADR (BNTX) News
Filter BNTX News Items
BNTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BNTX News From Around the Web
Below are the latest news stories about BIONTECH SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
BioNTech Positioned For Solid Growth Amid Oncology Transition: AnalystOn Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:PFE). BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development and upcoming catalysts. The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023. Als |
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid SpikeModerna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests. |
Private equity firms who hold 43% of BioNTech SE (NASDAQ:BNTX) gained 6.8%, institutions profited as wellKey Insights Significant control over BioNTech by private equity firms implies that the general public has more power... |
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.For pharmaceutical stocks, there are few events as crucial as the results of clinical trials for new drugs. |
NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan StanleyMorgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the National Institutes of Health and University of Pennsylvania regarding past and future royalties on the company and partner Pfizer’s (PFE) COVID vaccine, Comirnaty. Noting that the deal will result in two low-single digit percentage royalties on forward sales of Comirnaty and the companies will pay $1.15B for historical royalties, the firm says it views this as |
BioNTech to pay $467M in settlement agreement with University of PennsylvaniaIn a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 23, 2024, the Company entered into a binding term sheet with Penn to provide terms on which the Company retains license rights under certain Penn patent rights in order to |
BioNTech to pay $791.5M in settlement agreement with the NIHIn a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the National Institutes of Health concerning royalties and other related amounts allegedly owed on sales of the Company’s, and its collaboration partner, Pfizer’s (PFE) COVID-19 vaccine since commercialization. On December 20, 2024, the Company entered into a settlement agreement with the NIH. Under the terms of the Settlement Agreement, the Company will, among other things, pay $791.5M, |
BioNTech Settles Royalty Dispute with NIH for $791.5 MillionBioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, developed in collaboration with Pfizer. The settlement involves a payment of $791.5 million to the NIH, resolving past claims and adjusting future royalty arrangements. The settlement does not imply any admission of liability by BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlemen |
BioNTech Settles Royalty Dispute with University of PennsylvaniaThe latest update is out from BioNTech SE ( (BNTX) ). BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn, which includes royalties for past sales and funding for extended research collaboration. Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a |
BioNTech Announces Settlement With National Institutes of Health, University of Pennsylvania Over Royalty ClaimsBioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health an |